Therachon
Webb25 mars 2024 · Therachon is committed to making a difference in the lives of patients living with serious rare disorders. For more information, please visit … Webb5 sep. 2024 · Therachon Holding AG has developed products for the treatment of achondroplasia and short bowel syndrome.These include product candidate TA-46 for the treatment of achondroplasia, “a genetic condition and the most common form of short-limbed dwarfism”, as was reported in a press release from Pfizer.The U.S. …
Therachon
Did you know?
Webb25 mars 2024 · BASEL, Switzerland, March 25, 2024 /PRNewswire/ -- Therachon AG ("Therachon"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative ... Webb31 jan. 2024 · The investigational drug, one of an early generation drummed up by the buzzy AI tools in biotech, works by inhibiting multiple tropomyosin-related kinases, which …
WebbVP Biology at Therachon. Location: Basel, Canton of Basel-Stadt, Switzerland. Dr. Jeffrey Stavenhagen brings 20 years of scientific leadership experience in both the US and … Webb1 juli 2024 · Early clinical development program for achondroplasia augments Pfizer’s Rare Disease portfolio ... April 13, 2024
Webb13 mars 2024 · Therachon was focused on the discovery and development of therapeutics for rare pediatric conditions, and was acquired by Pfizer, Inc., in 2024 for $810 million. … WebbFresh off a $60 million raise, the Novo Holdings-backed startup Therachon announced plans to buy GLyPharma Therapeutic and make the leap to becoming a multi-asset rare disease company.
Webb29 nov. 2024 · Apraglutide, with once-weekly administration, is a potential best-in-class therapeutic for the treatment of short bowel syndrome. BASEL, Switzerland, Nov. 29, 2024 /PRNewswire/ -- Therachon AG ...
WebbHQ / GMP : #712-715, Sagimakgol-ro 137, Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea 13202 R&D Center : #1004-1005, Galmachiro 302, Jungwon-gu, Seongnam-si, Gyeonggi … focus coffee tableWebbTherachon 1,172 followers on LinkedIn. Life-Transforming Therapies - Developing novel therapeutics for serious rare conditions Therachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions for which there is significant unmet medical need. focus coffee podsWebbDevelopment group, serving as its Global Head for Integration Management and Global Head of Alliance Management. His work included the integration of Wyeth, Hospira, Anacor, Medivation, Therachon, Array and most recently Amplyx. He also directly led the separation of. 09 Apr 2024 21:53:51 focus coffee with superfoodsWebbPfizer is set to pay $340 million (€304 million) upfront to buy Therachon for Pfizer is set to pay $340 million (€304 million) upfront to buy Therachon for its treatment for a form of … greeting cards with cowsWebbFresh off a $60 million raise, the Novo Holdings-backed startup Therachon announced plans to buy GLyPharma Therapeutic and make the leap to becoming a multi-asset rare … greeting cards with hummingbird logoWebbTherachon General Information. Description. Developer of novel therapeutics intended to facilitate treatment for rare genetic diseases. The company develops pipeline of therapeutics focused on rare gastrointestinal and musculoskeletal disorders and conditions, enabling medical practitioners to treat patients with short bowel syndrome … focus cold chain 4.0Webb17 aug. 2024 · Therachon, a Swiss biotech company, has closed a $60 million round to fund its new developments in rare genetic disease treatments. focus collective